Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes.
Raffit Hassan(National Cancer Institute), Azam Ghafoor(National Cancer Institute), Emerson Padiernos(Center for Cancer Research), Manjistha Sengupta(National Institutes of Health), Cathy Wagner(National Institutes of Health), Seth M. Steinberg(National Institutes of Health), Jun S. Wei(Center for Cancer Research), Yvonne Mallory(National Institutes of Health), Anish Thomas(National Cancer Institute), Maria Agra(National Institutes of Health), Javed Khan(Kent State University), Idrees Mian(National Institutes of Health), Betsy Morrow(National Institutes of Health)
Cited by 22
Related Papers
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817